Activity enhancer for anticancer agent

Patent metadata

Field	Value
Publication number	US-9327013-B2
Application number	US-201214004196-A
Country	US
Kind code	B2
Filing date	Mar 9, 2012
Priority date	Mar 11, 2011
Publication date	May 3, 2016
Grant date	May 3, 2016

Abstract

An activity enhancer for an anticancer agent includes, as an active ingredient, a D-form amino acid residue-containing FNIII14 polypeptide, the D-form amino acid residue-containing FNIII14 being a polypeptide FNIII14 represented by SEQ ID NO: 1 in which at least one of amino acid residues at positions 1 to 13 is a D-form amino acid residue. An anticancer composition includes the activity enhancer for an anticancer agent and an anticancer agent.

First claim

The invention claimed is:

1. An activity enhancer for an anticancer agent against leukemia, comprising, as an active ingredient, a D-form amino acid residue-containing FNIII14 polypeptide, the D-form amino acid residue-containing FNIII14 being a polypeptide FNIII14 set forth in SEQ ID NO: 1 in which a glutamic acid residue that is an amino acid residue at position 2 is a D-form amino acid residue.

2. The activity enhancer for an anticancer agent against leukemia according to claim 1 , wherein the D-form amino acid residue-containing FNIII14 polypeptide is a D-form amino acid residue-containing FNIII14 polypeptide multimer.

3. The activity enhancer for an anticancer agent against leukemia according to claim 1 , wherein the anticancer agent is at least one selected from the group consisting of cytarabine (AraC), enocitabine, and elacytarabine.

4. A pharmaceutical composition for treatment of a leukemia, comprising the activity enhancer for an anticancer agent against leukemia according to claim 1 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition according to claim 4 , further comprising an anticancer agent.

6. An anticancer therapeutic agent set comprising a first container section in which the activity enhancer for an anticancer agent against leukemia according to claim 1 is contained, and a second container section in which an anticancer agent is contained.

7. A polypeptide that is either one of the following peptides:
(a) a polypeptide which is set forth in SEQ ID NO: 1, and in which a glutamic acid residue that is an amino acid residue at position 2 is a D-form amino acid residue; or
(b) a polypeptide which is a multimer, of which a constituent unit is the polypeptide (a).

8. The activity enhancer for an anticancer agent against leukemia according to claim 1 , the D-form amino acid residue-containing FNIII14 being a polypeptide FNIII14 set forth in SEQ ID NO: 1 in which a glutamic acid residue that is an amino acid residue at position 2 is a D-form amino acid residue.

9. A method for treating a leukemia, the method comprising administering, to a patient in need of treatment of leukemia, the activity enhancer for an anticancer agent against leukemia according to claim 1 .

Assignees

• Fukai Fumio
• Kodama Hiroaki
• Matsunaga Takuya
• Univ Tokyo Science Foundation
• Univ Saga
• Univ Kagawa Nat Univ Corp

Inventors

• Fukai Fumio
• Kodama Hiroaki
• Matsunaga Takuya

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K14/78

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K14/47

  from mammals · CPC title